{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:27:36Z","timestamp":1770996456623,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007660","name":"University of Antwerp","doi-asserted-by":"publisher","award":["FFB130136"],"award-info":[{"award-number":["FFB130136"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012220","name":"Hercules Foundation","doi-asserted-by":"publisher","award":["AUHA\/13\/03"],"award-info":[{"award-number":["AUHA\/13\/03"]}],"id":[{"id":"10.13039\/100012220","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fund for Scientific Research","award":["G.0412.16N"],"award-info":[{"award-number":["G.0412.16N"]}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marie Sk\u0142odowska Curie","award":["675527"],"award-info":[{"award-number":["675527"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vph.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T18:16:49Z","timestamp":1509473809000},"page":"34-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice"],"prefix":"10.1016","volume":"100","author":[{"given":"Bieke","family":"Van der Veken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido R.Y.","family":"De Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Martinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2017.10.004_bb0005","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2017.10.004_bb0010","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.ATV.0000178991.71605.18","article-title":"Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage","volume":"25","author":"Virmani","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.10.004_bb0015","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/14728222.2016.1186650","article-title":"Intraplaque neovascularization as a novel therapeutic target in advanced atherosclerosis","volume":"20","author":"Van der Veken","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.vph.2017.10.004_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mehy.2008.11.046","article-title":"Vasa vasorum hypoxia: initiation of atherosclerosis","volume":"73","author":"J\u00e4rvilehto","year":"2009","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.vph.2017.10.004_bb0025","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2007.12.025","article-title":"Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis","volume":"51","author":"Sluimer","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2017.10.004_bb0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/path.2518","article-title":"Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis","volume":"218","author":"Sluimer","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.vph.2017.10.004_bb0035","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jacc.2008.12.056","article-title":"Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage","volume":"53","author":"Sluimer","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2017.10.004_bb0040","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1253\/circj.CJ-11-0768","article-title":"Neovascularization and angiogenic factors in advanced human carotid artery stenosis","volume":"76","author":"Pelisek","year":"2012","journal-title":"Circ. J."},{"key":"10.1016\/j.vph.2017.10.004_bb0045","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/01.CIR.0000143233.87854.23","article-title":"Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability","volume":"110","author":"Moreno","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.10.004_bb0050","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.RES.0000020017.84398.61","article-title":"Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis","volume":"90","author":"De Meyer","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2017.10.004_bb0055","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1161\/CIRCULATIONAHA.109.872663","article-title":"Impaired fibrillin-1 function promotes features of plaque instability in apolipoprotein E-deficient mice","volume":"120","author":"Van Herck","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.10.004_bb0060","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/eurheartj\/ehu041","article-title":"Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death","volume":"36","author":"Van der Donckt","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2017.10.004_bb0065","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","article-title":"VEGF-receptor signal transduction","volume":"28","author":"Cross","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.vph.2017.10.004_bb0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ncb1486","article-title":"VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin","volume":"8","author":"Gavard","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.vph.2017.10.004_bb0075","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/01.CIR.98.20.2108","article-title":"Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions : possible pathophysiological significance of VEGF in progression of atherosclerosis","volume":"98","author":"Inoue","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.10.004_bb0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40959-015-0009-4","article-title":"Hypertension in cancer patients treated with anti-angiogenic based regimens","volume":"1","author":"Wasserstrum","year":"2015","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.vph.2017.10.004_bb0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1034\/j.1600-0897.2003.00073.x","article-title":"Effects of fibronectin, VEGF and angiostatin on the expression of MMPs through different signaling pathways in the JEG-3 cells","volume":"50","author":"Zhang","year":"2003","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.vph.2017.10.004_bb0090","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/CIRCULATIONAHA.104.495887","article-title":"Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation","volume":"111","author":"Khurana","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.10.004_bb0095","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cvr\/cvt148","article-title":"The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models","volume":"99","author":"Heinonen","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2017.10.004_bb0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/86490","article-title":"Vascular endothelial growth factor enhances atherosclerotic plaque progression","volume":"7","author":"Celletti","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.vph.2017.10.004_bb0105","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1161\/ATVBAHA.107.143743","article-title":"Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis","volume":"27","author":"Hauer","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.10.004_bb0110","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/01.RES.0000036901.58329.D7","article-title":"Accelerated atherosclerosis and calcification in vein grafts: a study in APOE*3 Leiden transgenic mice","volume":"91","author":"Lardenoye","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2017.10.004_bb0115","doi-asserted-by":"crossref","first-page":"A642","DOI":"10.1161\/atvb.34.suppl_1.642","article-title":"Abstract 642: vascular endothelial growth factor receptor 2 blockade in murine vein graft ameliorates lesion growth and enhances plaque stability by reducing intraplaque hemorrhage","volume":"34","author":"de Vries","year":"2014","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2017.10.004_bb0120","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2741\/1839","article-title":"VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy","volume":"11","author":"Rahimi","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.vph.2017.10.004_bb0125","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/01.RES.0000073584.46059.E3","article-title":"VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses","volume":"92","author":"Rissanen","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2017.10.004_bb0130","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.105.534107","article-title":"Gene transfers of vascular endothelial growth factor-a, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein","volume":"112","author":"Lepp\u00e4nen","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2017.10.004_bb0135","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","article-title":"Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis \u2013 implications for cardiovascular safety","volume":"168","author":"Winnik","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.vph.2017.10.004_bb0140","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.vph.2017.10.004_bb0145","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vph.2017.10.004_bb0150","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clgc.2012.12.004","article-title":"Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib","volume":"11","author":"Rini","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.vph.2017.10.004_bb0155","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.tranon.2014.04.002","article-title":"Axitinib improves radiotherapy in murine xenograft lung tumors","volume":"7","author":"Hillman","year":"2014","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.vph.2017.10.004_bb0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14740338.2014.888413","article-title":"Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies","volume":"13","author":"Bracarda","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.vph.2017.10.004_bb0165","first-page":"269","article-title":"Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma","author":"gross-goupil","year":"2013","journal-title":"Clin. Med. Insights Oncol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117301519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189117301519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T11:03:30Z","timestamp":1657710210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189117301519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":33,"alternative-id":["S1537189117301519"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2017.10.004","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}